Proteogenix는 Primary Antibody Biosimilar - Research Grade
제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.
제품 설명
제품 번호
PTXCOV-A521C
제품 특징
| Product name | Anti-CoV-RBD (E4) antibody |
|---|---|
| Species | Human |
| Expression system | Mammalian |
| Molecular weight | 150kDa |
| Purity | 85% |
| Buffer | PBS, pH7,5 |
| Form | Liquid |
| Delivery condition | Blue ice (+4°C) |
| Storage condition | 4°C for short term; -20°c or -80°C for long term |
| Brand | Proteogenix |
| Reference | PTXCOV-A521C |
| Note | For research use and in vitro diagnostic only. Not suitable for human use. |
| Isotype | IgG1 |
| Clonality | Monoclonal Antibody |
| Target | RBD domain- SARS-CoV2 Spike protein for first type and variants (PX-COV-P046, PX-COV-P052, PX-COV-P056) |
The anti-CoV-RBD (E4) antibody is an anti-SARS-CoV-2 with potential neutralizing activity identified by screening a vast COVID-19 antibody library (LiAb-SFCOVID-19™) against the receptor-binding domain (RBD) of the new coronavirus. Produced in IgG format, the variant was shown to be stable and to consistently yield high and consistent amounts when expressed in XtenCHO™, a transient mammalian expression system based on an engineered CHO cell line.
The specificity and affinity of this IgG antibody have been tested in ELISA (enzyme-linked immunosorbent assay) plates against the purified and recombinant form of the RBD. Additionally, the neutralizing capacity was confirmed indirectly using the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) assay, which was designed for the quick and accurate screening of antibody variants for their ability to block the interaction between RBD and its specific human receptor ACE2.
Since the beginning of the pandemic, numerous studies confirmed the therapeutic potential of SARS-CoV-2 NAbs (neutralizing antibodies). The reason for the preference of RBD over other domains of SARS-CoV-2 stems from its key role in the initiation of the viral infection. By blocking this important interaction, researchers expect to arrest the progression of the disease. Antibody therapeutics also presents a unique advantage over small molecules for the treatment of COVID-19. Most antiviral drugs are, in fact, known to suppress the immune response, which often delays the elimination of viral particles from the patient’s organism. On the contrary, antibody therapeutics further engage and activate the immune system of individuals, leading to a synergic action between the an antibody’s blocking activity and faster and safer viral clearance of pathogens.
In this context, research neutralizing antibodies such as anti-CoV-RBD (E4) serve to investigate the progression of the disease and the organism’s response to specific therapies.
QC & Validation Data
Anti-CoV-RBD (E4) antibody, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
ProteoGenix의 모든 제품들을 만나보세요!
Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"
MSDS
온라인 견적
